{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:37:03Z","timestamp":1793723823775,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["2015-703549"],"award-info":[{"award-number":["2015-703549"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jval.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T01:51:54Z","timestamp":1637718714000},"page":"622-629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Parametric Survival Extrapolation of Early Survival Data in Economic Analyses: A Comparison of Projected Versus Observed Updated Survival"],"prefix":"10.1016","volume":"25","author":[{"given":"Louis","family":"Everest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Blommaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambica","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jval.2021.10.004_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1470-2045(17)30423-0","article-title":"Measuring value and benefit-a matter of perspective","volume":"18","author":"Evans","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jval.2021.10.004_bib2","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1200\/JOP.17.00058","article-title":"Examining trends in cost and clinical benefit of novel anticancer drugs over time","volume":"14","author":"Saluja","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"11","key":"10.1016\/j.jval.2021.10.004_bib3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1001\/jama.2019.1153","article-title":"Choosing a time horizon in cost and cost-effectiveness analyses","volume":"321","author":"Basu","year":"2019","journal-title":"JAMA"},{"issue":"suppl 15","key":"10.1016\/j.jval.2021.10.004_bib4","article-title":"Reassessing the net health benefit of fda approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology value framework","volume":"38","author":"Delos Santos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.jval.2021.10.004_bib5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jval.2018.10.007","article-title":"Survival extrapolation in cancer immunotherapy: a validation-based case study","volume":"22","author":"Bullement","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2021.10.004_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12874-020-00997-x","article-title":"Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection","volume":"20","author":"Bullement","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2021.10.004_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hec.1444","article-title":"Uncertainty and validation of health economic decision models","volume":"19","author":"Kim","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2021.10.004_bib8","author":"Latimer"},{"issue":"3","key":"10.1016\/j.jval.2021.10.004_bib9","first-page":"205","volume":"22","author":"Bullement","year":"2019","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2021.10.004_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2021.10.004_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/biom.12384","article-title":"On the restricted mean survival time curve in survival analysis","volume":"72","author":"Zhao","year":"2016","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.jval.2021.10.004_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/cc7129","article-title":"Bench-to-bedside review: the importance of the precision of the reference technique in method comparison studies\u2013with specific reference to the measurement of cardiac output","volume":"13","author":"Cecconi","year":"2009","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.jval.2021.10.004_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jval.2021.10.004_bib14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from resonate: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jval.2021.10.004_bib15","author":"Group"},{"key":"10.1016\/j.jval.2021.10.004_bib16","author":"Lee"},{"issue":"12","key":"10.1016\/j.jval.2021.10.004_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes","volume":"32","author":"Ellis","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2021.10.004_bib18","doi-asserted-by":"crossref","unstructured":"Vreman RA, Bloem LT, Van Oirschot S, et\u00a0al. The role of regulator-imposed post-approval studies in health technology assessments for conditionally approved drugs [published online October 27, 2020]. Int J Health Policy Manag. https:\/\/doi.org\/10.34172\/ijhpm.2020.198.","DOI":"10.34172\/ijhpm.2020.198"},{"issue":"1","key":"10.1016\/j.jval.2021.10.004_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032884","article-title":"Developing a frame- work to incorporate real-world evidence in cancer drug funding decisions: the Canadian real-world evidence for value of cancer drugs (can\u2212 revalue) collaboration","volume":"10","author":"Chan","year":"2020","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.jval.2021.10.004_bib20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1017\/S0266462320000628","article-title":"Real-world data for health technology assessment for reimbursement decisions in asia: current landscape and a way forward","volume":"36","author":"Lou","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"issue":"9","key":"10.1016\/j.jval.2021.10.004_bib21","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","article-title":"Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations","volume":"37","author":"Ouwens","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2021.10.004_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0272989X20973201","article-title":"Extrapolating parametric survival models in health technology assessment: a simulation study","volume":"41","author":"Gallacher","year":"2021","journal-title":"Med Decis Making"},{"issue":"suppl 13","key":"10.1016\/j.jval.2021.10.004_bib23","doi-asserted-by":"crossref","first-page":"S1564","DOI":"10.21037\/jtd.2018.01.131","article-title":"Do immune checkpoint inhibitors need new studies methodology?","volume":"10","author":"Ferrara","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"issue":"2","key":"10.1016\/j.jval.2021.10.004_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40273-019-00853-x","article-title":"How uncertain is the survival extrapolation? A study of the impact of different parametric survival models on extrapolated uncertainty about hazard functions, lifetime mean survival and cost effectiveness","volume":"38","author":"Kearns","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2021.10.004_bib25","unstructured":"Everest L, D Tu, JL Pater, A Hay, MC Cheung, KK Chan. Restricted mean survival time within phase iii trials conducted by the Canadian cancer trials group: a comparison of survival analyses based on original and reconstructed individual patient data. In press."}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521017873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521017873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:26:41Z","timestamp":1761096401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521017873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1098301521017873"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.10.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parametric Survival Extrapolation of Early Survival Data in Economic Analyses: A Comparison of Projected Versus Observed Updated Survival","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}